These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32433984)

  • 21. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
    Buti M; Wong DK; Gane E; Flisiak R; Manns M; Kaita K; Janssen HLA; Op den Brouw M; Jump B; Kitrinos K; Crans G; Flaherty J; Gaggar A; Marcellin P
    Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):296-304. PubMed ID: 30795958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong CH; Lim SG
    Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
    Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
    J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.
    Höner Zu Siederdissen C; Rinker F; Maasoumy B; Wiegand SB; Filmann N; Falk CS; Deterding K; Port K; Mix C; Manns MP; Herrmann E; Wedemeyer H; Kraft AR; Cornberg M
    J Infect Dis; 2016 Nov; 214(10):1492-1497. PubMed ID: 27609808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
    J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
    Hall S; Howell J; Visvanathan K; Thompson A
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
    Lampertico P; Brunetto MR; Craxì A; Gaeta GB; Rizzetto M; Rozzi A; Colombo M;
    J Viral Hepat; 2019 Jan; 26(1):118-125. PubMed ID: 30187599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
    Liu Y; Jia M; Wu S; Jiang W; Feng Y
    Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.
    Kranidioti H; Manolakopoulos S; Kontos G; Breen MS; Kourikou A; Deutsch M; Quesada-Del-Bosque ME; Martinez-Nunez RT; Naiyer MM; Woelk CH; Sanchez-Elsner T; Hadziyannis E; Papatheodoridis G; Khakoo SI
    J Viral Hepat; 2019 Jun; 26(6):697-709. PubMed ID: 30702196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
    Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
    J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.